This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Investors Undervaluing GlaxoSmithKline (GSK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals
by Kinjel Shah
J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma
Glaxo Initiates Dosing in Phase III Meningitis Vaccine Study
by Zacks Equity Research
Glaxo (GSK) starts dosing with a phase III study on it 5-in-1 meningitis vaccine candidate.
Merck's Keytruda Positive in First-Line Esophageal Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda improves overall survival and progression-free survival compared to current standard of care in first-line metastatic esophageal cancer patients.
FDA Nods to Emergent's (EBS) Narcan Shelf Life Extension
by Zacks Equity Research
Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.
Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.
Moderna Up on $1.5B Federal Funding for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) inks a deal with the U.S. government for supplying 100 million doses of mRNA-1273, its vaccine against COVID-19. Shares rise in pre-market trading.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
Bayer (BAYRY) Q2 Earnings & Sales Fall Y/Y, Guidance Tweaked
by Zacks Equity Research
Bayer's (BAYRY) earnings and sales fall year over year in the second quarter of 2020.
Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings
by Zacks Equity Research
Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.
Is GlaxoSmithKline (GSK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus
by Kinjel Shah
Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.
Gilead (GILD) Misses on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Gilead (GILD) reports weaker-than-expected results for the second quarter but ups annual guidance.
Glaxo (GSK) Q2 Earnings & Sales Miss Estimates, Decline Y/Y
by Zacks Equity Research
Glaxo (GSK) witnesses disruption from COVID-19 pandemic in Vaccines and reversal of stockpiling benefits from the first quarter in Pharmaceuticals and Consumer Healthcare, which hurt sales.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vaxart (VXRT) has been actively engaged in developing a coronavirus vaccine. Investors are likely to focus on progress of vaccine program on the Q2 earnings call.
Sanofi (SNY) Q2 Earnings Top Estimates, Sales Lag, EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats Q2 estimates for earnings while missing the same for sales. Gain from COVID-19 associated patient stockpiling in the first quarter reverses in this quarter. Stock up.
Glaxo (GSK) Misses Earnings & Revenue Estimates in Q2
by Zacks Equity Research
Glaxo misses both earnings and sales estimates in the second quarter of 2020. Stock down.
VBI Vaccines (VBIV) to Report Q2 Earnings: What's in Store
by Zacks Equity Research
VBI Vaccine (VBIV) will provide financial updates when it releases second-quarter 2020 results.
Pfizer (PFE) Q2 Earnings Top, Sales Hurt by Coronavirus, View Up
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings while missing the same for sales. It slightly raises its financial outlook for the year.
Coronavirus Vaccine Development Puts These Stocks in Focus
by Ritujay Ghosh
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.